Ocular Therapeutix Inc. (OCUL)
NASDAQ: OCUL
· Real-Time Price · USD
7.20
0.03 (0.42%)
At close: May 16, 2025, 3:59 PM
7.37
2.43%
After-hours: May 16, 2025, 06:02 PM EDT
Ocular Therapeutix Revenue Breakdown
| Period Ending | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 |
|---|---|---|---|
| Collaboration revenue Revenue | 262K | 573K | 1.04M |
| Collaboration revenue Revenue Growth | -54.28% | -44.74% | n/a |
| Product revenue, net Revenue | 63.46M | 57.87M | n/a |
| Product revenue, net Revenue Growth | +9.66% | n/a | n/a |
Operating Expense Breakdown
| Period Ending | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 | Jun 30, 2015 | Mar 31, 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selling, General, and Administrative Revenue | 30.5M | 25.44M | 22.81M | 29.66M | 24.33M | 17.27M | 17.9M | 19.36M | 19.96M | 18.88M | 18.72M | 17.93M | 16.62M | 16.67M | 17.65M | 16.99M | 15.75M | 13.39M | 12.48M | 11.3M | 12.31M | 12.69M | 12.93M | 12.28M | 8.71M | 7.41M | 5.51M | 5.31M | 5.49M | 5.18M | 7.47M | 10.56M | 9.3M | 5.53M | 3.92M | 4.46M | 3.79M | 3.73M | 3.25M | 3.27M | 2.76M |
| Selling, General, and Administrative Revenue Growth | +19.88% | +11.54% | -23.11% | +21.93% | +40.88% | -3.51% | -7.54% | -3.03% | +5.73% | +0.88% | +4.41% | +7.86% | -0.30% | -5.57% | +3.88% | +7.89% | +17.64% | +7.28% | +10.47% | -8.19% | -3.05% | -1.85% | +5.28% | +41.10% | +17.44% | +34.42% | +3.76% | -3.17% | +5.91% | -30.61% | -29.25% | +13.47% | +68.29% | +41.13% | -12.27% | +17.65% | +1.66% | +14.90% | -0.67% | +18.34% | n/a |
| Research and Development Revenue | 42.86M | 40.99M | 37.05M | 28.86M | 20.73M | 16.2M | 15.02M | 15.09M | 14.75M | 13.54M | 13.72M | 13.1M | 13.1M | 12.58M | 12.72M | 13.86M | 10.93M | 7.62M | 6.95M | 8.02M | 6.1M | 10.13M | 10.23M | 9.41M | 11.32M | 10.26M | 9.69M | 8.74M | 8.23M | 7.91M | 8.13M | 8.12M | 6.73M | 7.33M | 5.69M | 6.98M | 7.07M | 6.89M | 8.26M | 6.74M | 4.72M |
| Research and Development Revenue Growth | +4.56% | +10.62% | +28.41% | +39.17% | +28.03% | +7.83% | -0.50% | +2.35% | +8.89% | -1.28% | +4.73% | 0.00% | +4.15% | -1.11% | -8.23% | +26.83% | +43.32% | +9.68% | -13.34% | +31.53% | -39.77% | -1.07% | +8.72% | -16.82% | +10.32% | +5.92% | +10.75% | +6.30% | +4.03% | -2.68% | +0.11% | +20.63% | -8.17% | +28.88% | -18.52% | -1.34% | +2.72% | -16.66% | +22.54% | +42.89% | n/a |
| Sales and Marketing Revenue | 14.15M | 1.32M | 10.57M | 9.99M | 10.18M | -26.48M | 9.31M | 11.15M | 10.84M | 10.53M | 10.19M | 10.14M | 9.06M | 9.14M | 9.58M | 8.39M | 8.09M | 6.81M | 6.52M | 6.15M | 7.13M | 7.14M | 6.78M | 7.22M | 3.35M | 2.29M | 1.07M | 867K | 717K | 903K | 3.24M | 6.83M | 6.03M | 2.53M | 1.29M | 1.49M | 1.39M | 1.14M | 798K | 1.04M | 870K |
| Sales and Marketing Revenue Growth | +972.63% | -87.52% | +5.79% | -1.86% | -138.46% | -384.23% | -16.48% | +2.93% | +2.87% | +3.41% | +0.45% | +11.88% | -0.80% | -4.59% | +14.12% | +3.77% | +18.72% | +4.46% | +5.96% | -13.70% | -0.17% | +5.39% | -6.20% | +115.86% | +46.09% | +114.71% | +23.07% | +20.92% | -20.60% | -72.11% | -52.61% | +13.36% | +138.60% | +95.21% | -13.27% | +7.42% | +21.52% | +43.23% | -23.34% | +19.66% | n/a |